Inmed Pharmaceuticals Inc. ( (INM) ) has released its Q1 earnings. Here is a breakdown of the information Inmed Pharmaceuticals Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InMed Pharmaceuticals Inc. is a pharmaceutical company based in British Columbia, Canada, focused on developing proprietary drug candidates and manufacturing rare cannabinoids for the health and wellness sector. The company recently released its earnings report for the quarter ended September 30, 2025, highlighting its ongoing financial performance and strategic initiatives. During this period, InMed reported sales of $1.12 million, with a gross profit of $403,159. However, the company also faced a net loss of $1.73 million, reflecting its continued investment in research and development and general administrative expenses. Despite these challenges, InMed maintains a cash position of $9.33 million, which is expected to support operations into the fourth quarter of 2026. Looking ahead, the company remains committed to advancing its pharmaceutical and commercial segments, with a focus on achieving key milestones and exploring strategic partnerships to enhance its financial stability and market presence.